Characterisation of a novel group B oncolytic adenovirus, ColoAd1
<p>Developing high potent oncolytic virus with multimodal antitumour capabilities is crucial for realizing the full potential of oncolytic virotherapy in cancer treatment. ColoAd1 is a novel replicating chimeric group B adenovirus recently bioselected from a large library of recombinant virus...
Autor principal: | Di, Y |
---|---|
Outros Autores: | Seymour, L |
Formato: | Thesis |
Idioma: | English |
Publicado em: |
2011
|
Assuntos: |
Registos relacionados
-
Characterisation of a novel group B oncolytic adenovirus, ColoAd1
Por: Di, Y, et al.
Publicado em: (2011) -
Arming ColoAd1 with tumor necrosis factor alpha and lymphotoxin alpha
Por: Koelen, J
Publicado em: (2015) -
Investigating the oncolytic properties of a group B adenovirus on cancer cells and its effects on the local immune response
Por: Calderon, H
Publicado em: (2017) -
Exploring the relationship between cancer metabolism and oncolytic adenoviruses
Por: Dyer, A
Publicado em: (2021) -
Bioprocessing of oncolytic group B adenovirus for scalable production
Por: Cooper, L
Publicado em: (2014)